AbioCor patient dies, device operation blamed:
This article was originally published in Clinica
The 13th patient to have received Abiomed's AbioCor heart replacement as part of a trial of the device has died of causes related to the device's operation. The Danvers, Massachusetts firm, which recently submitted a US marketing application for the device, said that together with the US hospital where the implantation was performed, it is investigating the situation and will release a report when an analysis has been completed. The patient had been supported by the device for 147 days. Candidates for the AbioCor clinical trial have a high probability of dying in less than 30 days.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.